Mentzel S, Assmann K J, Dijkman H B, de Jong A S, van Son J P, Wetzels J F, Koene R A
Department of Pathology, University Hospital Nijmegen, The Netherlands.
Nephrol Dial Transplant. 1996 Nov;11(11):2163-9. doi: 10.1093/oxfordjournals.ndt.a027132.
The hydrolase aminopeptidase A is an important regulator of the renin-angiotensin system, since it inactivates its most vasoactive component angiotensin II (Ang II). A single i.v. injection of a monoclonal antibody against mouse aminopeptidase A (ASD-4) induces a membranous-like glomerulonephritis in mice, characterized by an acute albuminuria, that is not dependent on complement, the coagulation system, or inflammatory cells. We hypothesized that this albuminuria is the consequence of a reduction in aminopeptidase A enzyme activity, that might subsequently lead to an increase in Ang II levels. Aminopeptidase A enzyme activity was analysed in vitro by a fluorimetric enzyme assay and in vivo by enzyme histochemistry. The role of Ang II in the induction of albuminuria in this model was studied by measuring the renal aminopeptidase A mRNA expression in our model by a competitive PCR assay as an indirect measure of Ang II levels. In addition, the role of Ang II in this model was studied by preventing the formation of Ang II with the angiotensin-converting enzyme inhibitor enalapril or by blocking of the Ang II receptor with the AT1 receptor antagonist losartan. Only antibodies that were able to inhibit the aminopeptidase A enzyme activity in vitro and in vivo induced an acute albuminuria in mice. Renal aminopeptidase A mRNA expression was increased by injection of the anti-aminopeptidase A antibody. Both enalapril and losartan treatment reduced the acute albuminuria, measured 1 day after injection of a monoclonal antibody against aminopeptidase A, by 91% and 83%, respectively. It is concluded that the induction of acute albuminuria is correlated to the enzyme-inhibiting capacity of the anti-aminopeptidase A antibodies. This impaired enzymatic activity most likely leads to an increase in the levels of Ang II, the best known substrate of aminopeptidase A. The results of our additional experiments are in keeping with our hypothesis that Ang II mediates this acute albuminuria. Whether this occurs by an increase of blood pressure or by a growth factor-like effect remains to be defined by further studies in this model.
水解酶氨肽酶A是肾素-血管紧张素系统的重要调节因子,因为它能使该系统中最具血管活性的成分血管紧张素II(Ang II)失活。单次静脉注射抗小鼠氨肽酶A单克隆抗体(ASD-4)可在小鼠中诱发膜样肾小球肾炎,其特征为急性蛋白尿,且不依赖补体、凝血系统或炎症细胞。我们推测这种蛋白尿是氨肽酶A酶活性降低的结果,这可能随后导致Ang II水平升高。通过荧光酶法在体外分析氨肽酶A酶活性,并通过酶组织化学在体内进行分析。通过竞争性PCR测定法测量我们模型中肾氨肽酶A mRNA表达,作为Ang II水平的间接测量指标,研究了Ang II在该模型中诱发蛋白尿的作用。此外,通过用血管紧张素转换酶抑制剂依那普利阻止Ang II的形成或用AT1受体拮抗剂氯沙坦阻断Ang II受体,研究了Ang II在该模型中的作用。只有在体外和体内均能抑制氨肽酶A酶活性的抗体才会在小鼠中诱发急性蛋白尿。注射抗氨肽酶A抗体可使肾氨肽酶A mRNA表达增加。依那普利和氯沙坦治疗均降低了注射抗氨肽酶A单克隆抗体1天后测得的急性蛋白尿,分别降低了91%和83%。得出的结论是,急性蛋白尿的诱发与抗氨肽酶A抗体的酶抑制能力相关。这种酶活性受损很可能导致氨肽酶A最知名底物Ang II水平升高。我们额外实验的结果与我们的假设一致,即Ang II介导这种急性蛋白尿。这是通过血压升高还是通过生长因子样作用发生,仍有待在该模型中进行进一步研究来确定。